IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0294590.html
   My bibliography  Save this article

Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study

Author

Listed:
  • Machiko Kai
  • Hayato Hikita
  • Maesaka Kazuki
  • Yuki Tahata
  • Kazuma Shinkai
  • Akira Doi
  • Kazuyoshi Ohkawa
  • Masanori Miyazaki
  • Hisashi Ishida
  • Kengo Matsumoto
  • Yasutoshi Nozaki
  • Takayuki Yakushijin
  • Ryotaro Sakamori
  • Akira Kaneko
  • Sadaharu Iio
  • Takatoshi Nawa
  • Naruyasu Kakita
  • Naoki Morishita
  • Naoki Hiramatsu
  • Takeo Usui
  • Kazuho Imanaka
  • Yoshinori Doi
  • Mitsuru Sakakibara
  • Yuichi Yoshida
  • Tsugiko Oze
  • Takahiro Kodama
  • Tomohide Tatsumi
  • Tetsuo Takehara

Abstract

The treatment efficiency and predictors of atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma in real-world practice have not been established. This study aimed to assess the efficacy and safety of atezolizumab plus bevacizumab and to investigate predictors of progression-free survival and overall survival. Patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy in 19 hospitals were enrolled before treatment and observed prospectively. The outcomes of 222 patients in this cohort were analyzed. The objective response rate and disease control rate were 22.0% and 70.6%, respectively, whereas the median progression-free survival was 5.7 months. Independent risk factors for shortened progression-free survival were younger age (

Suggested Citation

  • Machiko Kai & Hayato Hikita & Maesaka Kazuki & Yuki Tahata & Kazuma Shinkai & Akira Doi & Kazuyoshi Ohkawa & Masanori Miyazaki & Hisashi Ishida & Kengo Matsumoto & Yasutoshi Nozaki & Takayuki Yakushij, 2024. "Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study," PLOS ONE, Public Library of Science, vol. 19(1), pages 1-15, January.
    • Handle: RePEc:plo:pone00:0294590
    DOI: 10.1371/journal.pone.0294590
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0294590
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0294590&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0294590?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0294590. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.